Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AUY922 plus trastuzumab in second-line HER2-positive advanced gastric cancer
2011-002570-23Phase 2Terminated
- Sponsor
- Novartis
- Start
- Sep 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Luminespib and trastuzumab in gastric cancer (GC) and HER2-overexpressing gastric carcinoma, sponsored by Novartis. Primary endpoint: Overall Response Rate. Started Sep 2011; status: terminated.
02
Drugs
Luminespibtrastuzumab
03
Conditions
gastric cancer (GC)HER2-overexpressing gastric carcinoma
Beyond the preview
Go deeper on 2011-002570-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002570-23.